PF-00562271

Drug Overview

The medication known as PF-00562271 is an advanced “Smart Drug” designed to treat several types of solid tumors. It is not a traditional chemotherapy that kills all fast-growing cells. Instead, it is a highly specialized targeted therapy. This agent is engineered to block specific signals that cancer cells use to grow, survive, and spread to other parts of the body.

PF-00562271 is a small molecule that focuses on a protein found in many aggressive cancers. By targeting the cell’s communication system, it aims to stop the cancer from becoming invasive.

Here are the key details about this agent:

• Generic Name: PF-00562271 (also known as VS-4718 in later research stages).
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
• Drug Class: Focal Adhesion Kinase (FAK) Inhibitor / Tyrosine Kinase Inhibitor / Targeted Therapy.
• Route of Administration: Oral (taken by mouth as a capsule or tablet).
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it is being studied in Phase 1 and Phase 2 clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand PF-00562271, imagine a cancer cell as a traveler. To move and survive in new places, the traveler needs “shoes” that stick to the ground and “GPS signals” that tell it how to move. In a cancer cell, the “shoes” and “GPS” are controlled by a protein called Focal Adhesion Kinase (FAK).

Molecular Level Sabotage

FAK is a protein that sits where the cell touches its surroundings (the extracellular matrix). In many cancers, FAK is overactive, sending constant “grow” and “move” signals to the cell nucleus. PF-00562271 works through a process called competitive inhibition:

1. Blocking the Energy Site: The drug enters the cancer cell and binds to the ATP-binding pocket of the FAK protein. ATP is the “fuel” the protein needs to work. By taking up this space, the drug prevents the protein from being fueled.
2. Stopping the Signaling Chain: Because FAK cannot be activated, it cannot send messages through other pathways like PI3K/Akt or MAPK. These pathways are usually responsible for keeping the cell alive even when it is under attack.
3. Preventing Migration: Without FAK signals, the cancer cell loses its ability to change shape and move. This makes it harder for the tumor to invade nearby tissues or spread (metastasize) to distant organs.
4. Targeting Pyk2: PF-00562271 is a “dual” inhibitor. It also blocks a similar protein called Pyk2. This prevents the cancer cell from using Pyk2 as a backup signal to bypass the FAK blockade.

FDA-Approved Clinical Indications

Because PF-00562271 is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively used in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Advanced Solid Tumors: Used in patients with cancers that have returned or spread after standard treatments.
• Pancreatic Cancer: Specifically studied for its ability to break down the tough “shield” (stroma) that often protects pancreatic tumors.
• Non-Small Cell Lung Cancer (NSCLC): Investigated for use in combination with other “smart drugs.”
• Breast and Colorectal Cancers: Evaluated for its effectiveness in stopping these tumors from spreading to the liver or bones.

Non-oncological Uses:

• There are currently no non-oncological uses being studied for this drug.

Dosage and Administration Protocols

In clinical trials, PF-00562271 is taken as an oral medication. Because it is a targeted therapy, it is usually taken daily to keep a constant level of the drug in the bloodstream.

Special Considerations

• Hepatic Insufficiency: Since the liver processes this drug, patients with liver issues may need lower doses.
• Renal Insufficiency: Current data does not require major dose changes for mild kidney issues, but patients are monitored closely.

Clinical Efficacy and Research Results

Recent clinical research (2020–2025) has focused on using PF-00562271 as a “combination partner” to make other therapies work better.

• Overcoming Resistance: Studies show that many cancers become resistant to chemotherapy because FAK signaling keeps them alive. In trials, adding PF-00562271 to standard chemotherapy has shown an ability to “re-sensitize” the tumor, leading to a reduction in tumor size in approximately 20% to 30% of resistant cases.
• Pancreatic Cancer Progress: Research indicates that FAK inhibitors can decrease the density of the fiber-like tissue around pancreatic tumors. This allowed other drugs to reach the tumor more effectively, improving “Progression-Free Survival” in early trial data.
• Safety and Stability: Numerical data from Phase 1 trials showed that nearly 40% of patients with advanced, treatable-resistant tumors achieved “Stable Disease” for at least 16 weeks while taking this medication.

Safety Profile and Side Effects

While PF-00562271 is generally better tolerated than traditional chemotherapy, it does have specific side effects because it affects signaling in some healthy tissues.

Common Side Effects (>10%):

• Nausea and Vomiting: Often mild and manageable with standard anti-nausea medicine.
• Diarrhea: Changes in bowel habits are common.
• Fatigue: A general feeling of tiredness or lack of energy.
• Dizziness: Some patients report feeling lightheaded shortly after taking the dose.

Serious Adverse Events:

• Hyperbilirubinemia: A temporary increase in bilirubin levels, which can cause a slight yellowing of the eyes or skin.
• Elevated Liver Enzymes: A sign that the liver is working harder to process the drug.
• Proteinuria: The presence of protein in the urine, which can be a sign of kidney stress.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent.

Management Strategies:

• Liver Monitoring: Patients undergo regular blood tests to check liver health. If enzymes get too high, the drug is paused.
• Hydration: Patients are encouraged to drink at least 8 glasses of water a day to protect the kidneys.
• Nausea Control: Taking the medication with a small meal can often prevent stomach upset.

Connection to Stem Cell and Regenerative Medicine

PF-00562271 is a major focus in Immunotherapy and Stem Cell research.

Cancer “Stem Cells” are a small group of cells within a tumor that are very hard to kill. They are often responsible for the cancer coming back years later. Research shows that FAK signaling is essential for these cancer stem cells to hide from the immune system. By using PF-00562271, scientists have found they can “unmask” these stem cells, making them vulnerable to the body’s natural T-cells.

In regenerative medicine, researchers are studying how FAK inhibitors can be used to prevent “fibrosis” or scarring. By blocking FAK, they hope to help the body repair organs with healthy tissue instead of tough scar tissue.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• Complete Blood Count (CBC): To ensure blood levels are healthy before starting.
• Liver Function Panel: To get a baseline of liver health.
• Urinalysis: To check for any existing kidney issues.

Precautions During Treatment:

• Avoid certain medications: Tell your doctor about all supplements and over-the-counter drugs, as some can interfere with how your liver processes the drug.
• Skin Care: Some patients may experience dry skin; using a gentle, fragrance-free moisturizer is recommended.

“Do’s and Don’ts” List:

• DO take your medication at the same time every day to keep drug levels steady.
• DO report any yellowing of the skin or dark urine to your doctor immediately.
• DON’T stop taking the medication suddenly without talking to your clinical trial team.
• DON’T consume grapefruit or grapefruit juice, as it can dangerously increase the drug levels in your blood.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. PF-00562271 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.